OmniSeq operates at the forefront of cancer diagnostics, specializing in immune and genomic profiling to guide therapeutic management for cancer patients with advanced solid tumors. The company serves oncologists and their patients, providing critical insights for immunotherapy and targeted therapy decisions. OmniSeq's business model revolves around its proprietary molecular sequencing assays, which analyze DNA and RNA to identify genetic alterations linked to drug responses. This enables personalized treatment plans based on curated evidence from pathologists. The company generates revenue by offering these advanced diagnostic tests to healthcare providers, ensuring timely and actionable results. OmniSeq's market includes hospitals, cancer treatment centers, and research institutions focused on precision medicine.

Keywords: cancer diagnostics, immunotherapy, genomic profiling, molecular sequencing, personalized treatment, DNA RNA analysis, advanced solid tumors, precision medicine, healthcare providers, therapeutic management.